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Residence time describes the how long a ligand is bound to its target, and is attracting interest in drug
discovery as a potential means of improving clinical efficacy by increasing target coverage. This concept,
as originally applied to antagonists, is more complicated for G-protein-coupled receptor (GPCR) agonists
because of the transiency of receptor responses (via desensitization and internalization). However, in
some cases sustained GPCR agonist responses have been observed, with evidence consistent with a role
for slow binding kinetics. We propose a model to explain our understanding of how residence time and
rebinding might influence sustained signaling by internalized receptors. We also highlight the
anticipated benefit for drug discovery of fully understanding and exploiting these phenomena to target
desirable receptor response profiles selectively.Introduction
Owing to their diverse roles in many physiological and patho-
physiological settings, G-protein-coupled receptors (GPCRs) rep-
resent important drug targets. Pharmacological characterization of
GPCR ligands has traditionally focused on potency and efficacy,
where concentration-dependent parameters are measured at (or
near) equilibrium. There is, however, a growing appreciation for
the clinical relevance of the temporal aspects of ligand–receptor
interactions [1,2].
Optimizing the properties of GPCR agonists to have a long
duration of action could seem like an attractive drug discovery
strategy, by increasing target activation and thereby improving
clinical efficacy, as has been highlighted for antagonists [1,2].
However, historical data and perceived wisdom suggest that agonist
responses are usually regulated by receptor desensitization and
internalization, which can act to limit the effect and duration of
receptor signaling. Therefore, the anticipated effects of prolonged
agonist binding could be negated by a loss of receptor function.
Nevertheless, it is becoming increasingly apparent that desen-
sitization does not always play a major regulatory part, and in
some cases downstream G-protein responses persist for extendedCorresponding author:. Rawlins, P. (philip.rawlins@astrazeneca.com)
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1359-6446/ 2015 The Authors. Published by Elsevier Ltperiods of time during continual agonist exposure (Table 1 lists
current examples). These findings suggest that the opportunity
can exist for a long duration of action to be specifically optimized
through understanding and targeting ligand-specific factors that
promote persistent agonist–receptor interactions. In this review,
we discuss the mechanisms proposed for sustained wash-resistant
receptor responses and evaluate the importance of ligand-depen-
dent properties such as slow dissociation kinetics and rebinding in
driving these effects. We conclude by highlighting the potential
value in targeting sustained signaling for future drug discovery
programs.
Sustained GPCR signaling
The classic model of GPCR function describes tightly regulated
responses that undergo desensitization and internalization upon
chronic agonist exposure. This typically involves phosphorylation
of agonist-activated receptors by G-protein-coupled receptor
kinases (GRKs) and/or other intracellular protein kinases followed
by recruitment of b-arrestin, as reviewed elsewhere [3,4]. However,
it now appears that not all GPCRs interact with b-arrestin [5–7]. It
is possible that these receptors can therefore avoid conventional
desensitization mechanisms and demonstrate persistent agonist
responses from cell-surface, noninternalized receptors (Table 1).d. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
http://dx.doi.org/10.1016/j.drudis.2015.07.015
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TABLE 1
Examples of GPCR subtypes demonstrating sustained signaling and some proposed mechanism(s) of action for sustained responses
Receptor Proposed mechanism(s) of sustained response Duration of sustained response Refs
Parathyroid hormone SSIR; residence time >50 mina [8]
Thyroid-stimulating hormone SSIR >30 mina [9]
Sphingosine-1 phosphate-1 SSIR; residence time and rebinding >300 mina [16,42]
b2-adrenergic SSIR; exosite; membrane deposition >180 mina or >10 minb [25,27,43,44]
Vasopressin-2 SSIR >40 mina [17]
Glucagon-like peptide SSIR n.d. [37]
Angiotensin-II SSIR >30 minb [45]
Calcitonin a SSIR; residence time > 4320 minb [18]
Serotonin 5-HT2B SSIR; residence time and rebinding >240 mina [19]
GPR119 Residence time or membrane deposition >180 mina [22]
Melanocortin 1 Residence time >120 mina [20]
Melatonin MT1 Residence time >180 mina [23]
Gonadotrophin-releasing hormone Cell surface; no b-arrestin >45 minb [5]
Bile acid TGR5 Cell surface; no b-arrestin >100 minb [6]
Relaxin RXFP1 and2 Cell surface; no b-arrestin >360 minb [7]
Adenosine A2A Cell surface >30 minb [46]
Muscarinic M1 Exosite >60 mina [21,38]
Abbreviations: GPCR, G-protein-coupled receptor; SSIR, sustained signaling by internalized receptors; n.d., not determined.
a The duration of sustained effect as defined by a significant level of receptor activation that remains after washout of agonist.
b The duration of sustained effect as defined by a significant level of receptor activation that remains after chronic continual agonist treatment.
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classic understanding of receptor internalization as a mechanism
for negatively regulating receptor responses, it has been demon-
strated that some GPCRs can continue to signal after internaliza-
tion. This sustained signaling by internalized receptors (SSIR)
permits prolonged G-protein signaling from intracellular compart-
ments (often endosomes). Ferrandon and colleagues [8] used
real-time cAMP measurements in conjunction with imaging of
fluorescently labeled receptors to measure the dynamics of para-
thyroid hormone (PTH) receptor signaling and trafficking. These
studies demonstrated that, contrary to initial expectations, cAMP
signaling was not diminished when there was a concurrent loss
of cell-surface receptors by internalization. Instead, receptors co-
localized with the necessary signaling machinery in endosomes
post agonist stimulation and, remarkably, inhibition of endocy-
tosis reduced cAMP responsiveness.
SSIR has also been reported for a number of other diverse GPCR
subtypes (Table 1), perhaps indicating that this phenomenon can
in fact represent a more widespread mechanism of GPCR function.
Not only can SSIR promote extended receptor responses but
there is also evidence that G-protein signals generated from intra-
cellular compartments can be functionally distinct from those at
the cell surface [9,10]. Moreover, internalization can also facilitate
sustained G-protein-independent mitogen-activated protein ki-
nase (MAPK) signaling by GPCRs [11,12]. Internalization can
therefore have a significant impact on the regulation and func-
tional outcomes of receptor signaling.
Does the agonist need to be there?
Surprisingly, a gap in our basic understanding of GPCR function is
related to the role of the agonist after it has activated the receptor.It might seem intuitive that throughout the duration of signaling
the receptor must be in a continual agonist-bound activated state,
but there is little direct evidence for this.
Clues toward whether agonist–receptor binding remains intact
after endocytosis come from studies examining the subcellular
localization of fluorescently tagged agonists and receptors. A
number of peptide agonists have been demonstrated to co-inter-
nalize and intracellularly co-localize with their cognate receptors
[8,9,13]. This has also been observed for small-molecule adrenergic
and adenosinergic receptor agonists [14,15]. Furthermore, real-
time whole-cell binding experiments with PTH receptor demon-
strated that the agonist remained receptor-bound throughout
the time-course of sustained endosomal responses, despite the
loss of cell-surface receptors by internalization [8].
Strong evidence for functional consequences of post-endocytic
binding interactions comes from studies examining the influence
of enzymatic degradation of neurokinin-1 receptor agonists [12].
An endosomal agonist-receptor-b-arrestin complex that signals
through MAPK is terminated by degradation of the agonist within
endosomes, suggesting a requirement for continual binding in
these compartments.
Ligand properties that favor persistent receptor
interactions
If continual agonist binding is required for sustained signaling
then it is likely that these responses will be facilitated by agonist-
specific properties that prolong interactions with the receptor.
Using in vitro experiments this can be exhibited by ‘wash-resistant’
receptor activation, where signaling continues even after excess
agonist is removed from the receptor by infinite dilution of the
drug-containing buffer [8,9,16–22]. It is anticipated that this couldwww.drugdiscoverytoday.com 91
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clearance from the body. We have identified the main mecha-
nisms that can explain persistent activation, which are also sum-
marized in Fig. 1.
i Residence time. This describes the duration of ligand–receptor
interactions. Long residence time could drive sustained
receptor activation through a single preformed stable binding
event that persists after removal of unbound agonist (Fig. 1a),
as has been implicated for a number of GPCR agonists
[18,20,22,23]. In the simplest model, ligand binds to receptor
to form ligand–receptor complexes and, in binding kinetic
experiments, residence time is calculated at the reciprocal of
the rate of dissociation (Koff) of these complexes (Eqn 1).Plasma membrane 
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FIGURE 1
Ligand properties that favor persistent wash-resistant receptor activation in
in vitro experiments. Left-hand images describe agonist (blue circles) and
receptor (red circles) interactions formed during exposure to excess agonist.
Right-hand images describe agonist–receptor interactions that remain after
removal of excess agonist by washing. (a) Residence time: slow dissociation
of the ligand permits binding events pre-established during agonist exposure
to remain after unbound ligand is removed because the bound ligand does
not dissociate over the time-course of the experiment. (b) Rebinding: dilution
of free ligand in the surrounding buffer is not sufficient to remove the ligand
from the vicinity of the receptor because upon dissociation from the receptor
the ligand is more likely to bind again than diffuse away. Thus, new binding
events are established after washing. (c) Exosite: one part of the ligand (green
circles) tethers it to the vicinity of the receptor (the ‘exosite’), allowing the
pharmacologically active part (blue circles) to access the receptor-binding
site. Thus, it is free to associate and dissociate after excess agonist is removed.
(d) Sustained signaling by internalized receptors (SSIR): agonist drives
internalization of the receptor, and from intracellular compartments (e.g.
endosomes) it can continue to activate the receptor. This traps the agonist
inside these compartments, allowing responses to continue after washing.
92 www.drugdiscoverytoday.comii Rebinding. This describes a phenomenon where, upon
receptor dissociation, a ligand is more likely to bind again
rather than diffuse away and discontinue its influence [24]
(Fig. 1b). Therefore, rather than persistent occupation of the
binding site per se, factors that hinder the removal of the
ligand from the vicinity of the receptor can also cause
prolonged effects through promoting the opportunity for
multiple new binding events after removal of excess ligand.
This could be linked to physiochemical properties of the
ligand because lipophilic compounds can partition into
cellular membranes and subsequently access the receptor-
binding site from (or through) the membrane environment
after removal of free agonist in the aqueous phase. Sustained
agonist effects via this mechanism have been suggested for
the b2-adrenergic receptor [25,26] and GPR119 [22].
iii Exosite. An exosite hypothesis (Fig. 1c) has also been proposed
for long-acting b2-adrenerigc agonists [27] as well as the
muscarinic M1 agonist xanomeline [21], and can be viewed as
an extreme example of rebinding. This involves one part of the
ligand persistently interacting with a secondary binding site
on or near the receptor (the ‘exosite’), bringing the pharma-
cologically active head group into the proximity of the
receptor-binding site and allowing multiple cycles of dissocia-
tion and reassociation.
iv SSIR. Agonist-driven receptor internalization promotes signal-
ing from intracellular compartments (Fig. 1d). Internalization
can allow a more prolonged agonist response [8,9], perhaps by
avoiding conventional cell-surface desensitization mecha-
nisms.
Ligand properties driving SSIR
Clearly, the ability of a given agonist to promote SSIR will depend
on its ability to cause receptor internalization. However, is it
sufficient for an agonist to drive internalization for it to evoke
SSIR; or can other ligand-specific factors that influence the dura-
bility of ligand binding effect the generation and maintenance of
SSIR? In other words, are binding kinetics and rebinding still
important phenomena in controlling the duration of signaling
from internalized receptors, as they are for those receptors at the
cell surface?
Anecdotal evidence suggests that agonist dissociation kinetics
can regulate whether a ligand can evoke SSIR. For PTH receptor,
calcitonin and serotonin 5-HT2B receptors the observation of SSIR
appears to be characteristic of agonists with slow dissociation from
these receptors, while being absent with rapidly dissociating li-
gands [8,18,19]. It is therefore tempting to speculate that long
residence time is a general feature of SSIR agonists, although this
remains to be characterized for other receptors. However, addi-
tional evidence suggests that long residence time alone is not
sufficient to support SSIR but that rebinding is also important.
The duration of SSIR measured for 5-HT2B agonists is longer than
their residence times [19], suggesting that multiple independent
binding events are likely to be involved (i.e. a single binding event
is not sufficiently long). Moreover, SSIR observed for 5-HT2B and
sphingosine-1 phosphate (S1PR) receptors can be reversed with
antagonists [16,19]. This can be considered a hallmark of rebinding
Drug Discovery Today  Volume 21, Number 1  January 2016 REVIEWS
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of sustained responses, assuming that the antagonists used are
orthosteric and capable of passing cellular membranes to access
intracellular receptor-binding sites. Because of the ‘outside in’ na-
ture of membrane rearrangements during endocytosis, internalized
agonists will be found inside intracellular compartments (Fig. 1d).
This can result in increased local concentrations of the agonist as it is
trapped within a spatially confined yet receptor-enriched environ-
ment, promoting opportunities for rebinding events [28].
Residence time and rebinding could interact to regulate SSIR,
thus explaining how slow dissociation kinetics is important but
not sufficient for it. Interestingly, there is evidence linking agonist
off-rate with an ability to induce S1PR endocytosis-dependent
responses and that the agonist must be bound long enough to
co-internalize with the receptor [29]. It is plausible that a threshold
residence time is required for agonist–receptor co-internalization
events and subsequently the generation of SSIR. We speculate that
a single binding event can be sufficient to initiate SSIR, but it is
maintained by multiples of these events (rebinding) to exacerbate
response duration.Plasma m
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FIGURE 2
Model that predicts how sustained signaling by internalized receptors (SSIR) depend
in a hypothetical receptor system. (a) The red line on the graph shows the rate of re
The blue bars superimposed onto this represent the residence times of three agon
internalization rate with residence time it can be seen that agonist A remains boun
when only a small proportion are internalized and agonist B is intermediate. (b) For
occurs. This permits activation of the receptor from endosomes after internalization
trapped within endosomes, which is predicted to promote rebinding and prolong t
level of agonist–receptor co-internalization will occur. (c) By contrast, agonist C does
evoke SSIR. The functional consequences of these differences are linked to qualitat
based on its subcellular localization: G-proteins X and Y and MAPK, as well as theModel: residence time regulates SSIR
Based on the literature and internal unpublished observations, we
have proposed a model to help understand the contribution of
residence time and rebinding for SSIR. Figure 2a describes a hypo-
thetical receptor system that displays agonist-driven internaliza-
tion with a half-life of 3 min, which represents a typical GPCR
endocytic rate based on observations in the literature [8,30,31].
The receptor system also has the capacity for receptor signaling
from intracellular compartments. We speculate that the residence
time of an agonist relative to receptor internalization rate will
determine the proportion of agonist co-internalized with the
receptor. Based on measurements made at 378C for multiple
receptor systems, GPCR ligands have been observed to have resi-
dence times ranging from less than a minute to a number of hours
[8,18,23,32,33]. In this model we describe ligands that fall within
this range. Agonist A has a residence time of 10 min and therefore
remains bound for sufficient time to internalize in a complex with
the receptor (Fig. 2b). This results in a continued ability to activate
the receptor from intracellular compartments (SSIR). By contrast,
agonist C has a residence time of 1 min, so significantly shorterG-protein X 
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s on agonist residence time by regulating agonist–receptor co-internalization
ceptor internalization after commencement of agonist exposure (t½ = 3 min).
ists: 10, 5 and 1 min for agonists A, B and C, respectively. Comparing receptor
d when the majority of receptors are internalized, agonist C remains bound
 agonist A, therefore, robust co-internalization of agonist–receptor complexes
, thus eliciting SSIR. It can be seen that once this has occurred the agonist is
he effects of the ligand. Agonist B will elicit a partial SSIR response as a lower
 not co-internalize with the receptor to the same extent and can therefore not
ive differences in the signaling pathways through which the receptor signals
 duration of activation thereof.
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most of the receptors have internalized, preventing it from acces-
sing these signaling cascades (Fig. 2c).
Therefore, the outcomes of activation by agonists A and C are
predicted to be functionally distinct as a consequence of whether
their dissociation kinetics are slow enough to meet the threshold
residence time required for co-internalization with the receptor.
As well as evoking more-prolonged signaling, agonist A might
be further differentiated via activation of qualitatively different
G-protein cascades (X and Y in Fig. 2), and the ability to access
endosomal MAPK pathways.
Once SSIR is initiated, the agonist is spatially confined within
intracellular compartments, enriching its local concentration and
therefore increasing the potential to bind to the receptor multiple
times (i.e. rebinding). Importantly, this could maintain a response
duration that is far longer than that governed by a single binding
event (i.e. purely residence-time-driven). To reiterate, we predict
that residence time can regulate whether or not SSIR is triggered,
but the duration of the response can be subsequently influenced
by rebinding events.
Because there is limited published experimental data available
to verify the relationship between agonist residence time and
agonist–receptor co-internalization, this model is speculative.
We therefore propose the following approaches to test the assump-
tions of the model. First, a direct comparison of receptor internali-
zation rates and ligand-binding kinetics for a panel of agonists
will be crucial. Second, an assessment of putative correlations
between GPCR agonist residence time and the observation of
agonist–receptor co-internalization events will be key to under-
standing whether a threshold residence time is required. This
could be achieved by co-imaging fluorescently tagged ligands
and receptors. Third, proposed post-internalization intracellular
agonist–receptor binding could potentially be monitored by
adapting current Fo¨rster resonance energy transfer (FRET)-based
whole-cell binding assays [8,34,35] under conditions of endocyto-
sis inhibition or by selectively removing cell-surface FRET signals.
Fourth, the role of rebinding could be assessed by applying well-
characterized cell-permeant orthosteric antagonists to disrupt in-
tracellular agonist binding or signaling, while comparing the
effect of cell-inpermeant antagonists. And, finally, where there
has been clear demonstration of ligand-specific SSIR, such as in
the case of vasopressin and oxytocin at the vasopressin V2 receptor
[17], we propose intriguing follow-up studies to compare the
binding kinetics of these ligands directly.
Relevance to clinical efficacy
Long duration of action (preferably 24 hours) is an important
feature of drugs intended to treat chronic illness, and there is
evidence that this could be achieved for GPCR antagonists via long
residence time, thus improving their clinical efficacy [1]. However,
despite a prominent role for many GPCR agonists in the clinic, the
relevance of residence time for these ligands remains poorly
understood.
If the outcome and duration of receptor responses to agonists
can be influenced by residence time, this offers the exciting
opportunity to exploit binding kinetics to optimize the temporal
and functional response profiles of future drug candidates. Thus, a
more selective pharmacotherapeutic response could be targeted to94 www.drugdiscoverytoday.comimprove clinical efficacy and safety. For example, a long or short
duration of action might be preferred or only part of the response
repertoire of the receptor activated. Although prolonged receptor
effects are likely to be advantageous in many cases, it must also be
considered that developing drugs with a shorter duration of action
could be preferential where target-based toxicity is a problem [1].
Thus, under some circumstances, optimizing a lack of SSIR might
provide a better drug candidate.
Interestingly, long- and short-acting PTH receptor agonists have
been proposed to have distinct potential clinical applications
(hypoparathyroidism and osteoporosis, respectively) based on
their differences to evoke SSIR [36], whereas SSIR of ergot 5-
HT2B agonists has been postulated to confer cardiac valvulopathic
side effects of these ligands [19]. Moreover, the clinical efficacy
of the S1P1R immunomodulator drug FTY729P is proposed to be
linked to its long residence time that promotes persistent receptor
internalization and intracellular signaling [29]. Importantly, SSIR
has been observed for a growing list of endogenous ligands
[9,17,37], highlighting its potential physiological relevance.
Relevance to drug discovery approaches
Can we develop agonists that selectively promote sustained
signaling? In support of the potential to optimize this property,
differences in the ability of agonists to evoke sustained signaling
for the same receptor have been observed in a number of cases
[8,17–20,22,38]. This highlights the general ability to drive
divergent receptor responses in a ligand-selective manner. How-
ever, before these properties can be optimized in a predictable
and strategic manner it will be important to develop a more
detailed understanding of the mechanisms behind differentiated
agonist response profiles. For example, GPR119 agonists differ
not only in their ability to cause sustained activation but also in
the ligand-specific properties that cause the effect (residence time
vs membrane deposition) [22]. Interestingly, efforts have been
made to understand the SAR of the sustained effects of derivatives
of the muscarinic M1 agonist xanomeline, identifying potential
roles for hydrophobic interactions as well as exosite binding [38].
Similarly, a comparison of S1P1R agonists identified structural
features that correlate with the observation of SSIR [16]. Notably,
the ability to predict structure–kinetic relationships for GPCR
agonists has recently been reported, which could assist future
targeting of long residence time agonist compounds [39]. It is
anticipated that the emerging structural understanding of recep-
tor–ligand interactions driven by X-ray crystallization techniques
will significantly increase our understanding GPCR biology,
which could indirectly inform strategies to optimize ligand-
binding kinetics.
GPCR ligand-binding kinetics are too infrequently character-
ized, and only with more kinetic information can we better
understand and validate the role of agonist residence time in
regulating receptor function. We suggest that a number of impor-
tant considerations might be required to define agonist residence
time and SSIR properties fully.
i Putative receptor binding in intracellular compartments
during SSIR might not be equivalent to binding at the cell
surface because of the vast differences between the two
environments (e.g. space, pH, receptor density, receptor
regulatory states and protein–protein interactions).
Drug Discovery Today  Volume 21, Number 1  January 2016 REVIEWS
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noncellular systems, at below-physiological temperature, and/
or where no distinction is made between surface and
internalized receptors.
iii Whole-cell binding experiments performed at 378C could
provide more-appropriate kinetic information than mem-
brane fractions tested at low temperature. FRET-based ligand-
binding assays, as previously applied [8,34,35], could be
especially useful for whole-cell approaches because the
binding signal is specific for ligand–receptor interactions
without the need to wash unbound ligand. Therefore, binding
can be detected from the cell surface and intracellular
receptors after internalization events.
iv It might also be important to measure residence time at pH
relevant to intracellular compartments (e.g. pH < 6.5 for
endosomes).
v Because SSIR is likely to be cell-context-dependent, highly
artificial recombinant expression systems might not accurate-
ly predict in vivo responses. Studying physiologically relevant
systems such as primary cell lines or induced stem cell models
along with phenotypic screening approaches could be
beneficial and more appropriate for defining this mechanism
of action.
An attractive extension to our hypothesis is to consider that
differences between agonists in driving sustained signaling can be
viewed as a form of ligand bias, which has attracted much atten-
tion in drug discovery. Ligand bias is proposed to involve con-
formationally selective ligand binding to differentially promote
signaling from multiple active receptor states [40]. However, some
classic observations of ligand bias (e.g. selective MAPK signaling)
could be explained in part by residence time: how and where the
receptor signals are being controlled by agonist binding kinetics
(Fig. 2). It will be interesting to observe how the concepts of ligand
bias and residence time develop with future understanding.
Ultimately, the relevance of SSIR will only be fully understood
by testing agonists with different signaling properties in relevant in
vivo models. This also requires the impact of pharmacokinetics to
be considered. The majority of in vitro receptor assays are per-
formed under equilibrium conditions, which might not wholly
represent dynamic changes in ligand concentrations in vivo. A
recent model has highlighted that residence time can only influ-
ence in vivo duration of action if dissociation rate is slower than
elimination from the body [41]. Whereas this holds true for
antagonists, where the duration of binding is equal to the duration
of effect, GPCR agonist effects are inherently more complex be-
cause of the spatiotemporal dynamics of receptor activation.
Because residence time is predicted to regulate receptor signalingqualitatively it could operate somewhat independently of phar-
macokinetics. Moreover, long residence time that allows endoso-
mal co-localization and rebinding could exaggerate effect duration
long after extracellular elimination.
Concluding remarks
Recent observations that GPCR signaling can be stable over time
have highlighted the importance of temporal aspects of agonist-
response profiles. It remains unclear how agonist-specific proper-
ties might influence sustained responses. However, a better un-
derstanding of the interdependence of persistent ligand binding
and sustained receptor activation would offer greater clarity into
the pharmacological regulation of receptor activation. Conse-
quently, these phenomena could be selectively optimized and
exploited for drug discovery to achieve more selective ligand
response profiles. We envision that strategies to optimize agonist
residence time represent an appealing approach to target (or avoid)
sustained GPCR signaling selectively.
Here, we have theoretically examined how agonist residence
time can regulate SSIR, and highlighted experimental evidence to
support this. As an overview of the literature, it appears that,
where it has been tested, slow receptor dissociation is a charac-
teristic feature of agonists that elicit SSIR. However, this property
remains to be verified with a larger panel of agonist–receptor
pairings. Furthermore, it is likely that other factors such as
rebinding combine to enhance the effect of residence time on
the duration of signaling. Accordingly, we have devised a theo-
retical model that predicts a threshold residence time is needed to
initiate SSIR but that rebinding is required to maintain it for the
response duration observed in cellular experiments. This is based
on several assumptions, thus necessitating further experimental
work. In particular: does the agonist always need to remain
bound; is agonist–receptor co-internalization essential for SSIR;
and how valid is the concept of a requisite threshold residence
time?
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